GnRH agonists initially bind to GnRH receptors in the pituitary gland, causing a temporary surge in the production of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This surge is followed by a profound suppression of these hormones due to receptor downregulation. The result is a decrease in the production of testosterone in men and estrogen in women, hormones that can fuel the growth of certain types of cancer.
